← all works
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Prostate Cancer Treatment and Research
- Field
- Medicine
- Canadian institutions
- London Health Sciences Centre
- Funders
- —
- Keywords
- CabazitaxelMitoxantroneDocetaxelMedicineProstate cancerPrednisoneInternal medicineOncologyTaxaneEnzalutamideClinical endpointAbiraterone acetateHazard ratioRandomized controlled trialCancerSurgeryChemotherapyAndrogen deprivation therapyConfidence intervalBreast cancer
- Has abstract in OpenAlex
- no